Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate

Claude M. Wischik* (Corresponding Author), P. Bentham, S. Gauthier, S. Miller, K. Kook, B. O. Schelter

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)
2 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate'. Together they form a unique fingerprint.

Medicine & Life Sciences